TITLE

Therapeutic ratio of inhaled fluticasone

AUTHOR(S)
LIPWORTH, BRIAN J.
PUB. DATE
March 2000
SOURCE
Thorax;Mar2000, p252
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
No abstract available.
ACCESSION #
66877260

 

Related Articles

  • Untitled. Mckenzie, S. A. // Thorax;Dec2001, Vol. 56 Issue 12, p981 

    Presents a letter to the editor, on side effects of inhaled fluticasone, used to treat asthma.

  • Inhaled fluticasone propionate. A pharmacoeconomic review of its use in the management of asthma. Lamb, H.M.; Culy, C.R.; Faulds, D. // PharmacoEconomics;2000, Vol. 18 Issue 5, p487 

    Unlabelled: Contemporary asthma management guidelines list inhaled corticosteroids as the preferred controller medication for patients with persistent asthma. Despite the availability of explicit guidelines, there is evidence that these agents are underused and that guidelines are...

  • A Cost-Effectiveness Analysis of First-Line Controller Therapies for Persistent Asthma. Shih, Ya-Chen Tina; Mauskopf, Josephine; Borker, Rohit // PharmacoEconomics;2007, Vol. 25 Issue 7, p577 

    Background: Asthma is one of the most common chronic diseases in the US, and its prevalence continues to increase. Despite the availability of effective asthma controller medications, many patients with asthma are still not meeting therapeutic goals because of poor disease management. The high...

  • Montelukast and fluticasone compared with salmeterol and fluticasone in protecting against asthma exacerbation in adults: one year, double blind, randomised, comparative trial. Bjermer, Leif; Bisgaard, Hans; Bousquet, Jean; Fabbri, Leonardo M; Greening, Andrew P; Haahtela, Tari; Holgate, Stephen T; Picado, Cesar; Menten, Joris; Dass, S Balachandra; Left, Jonathan A; Polos, Peter G // BMJ: British Medical Journal (International Edition);10/18/2003, Vol. 327 Issue 7420, p891 

    Abstract Objectives: To assess the effect of montelukast versus salmeterol added to inhaled fluticasone propionate on asthma exacerbation in patients whose symptoms are inadequately controlled with fluticasone alone. Design and setting: A 52 week, two period, double blind, multicentre trial...

  • Inhaled salmeterol/fluticasone propionate combination. A pharmacoeconomic review of its use in the management of asthma. Markham, A.; Adkins, J.C. // PharmacoEconomics;2000, Vol. 18 Issue 6, p591 

    Cost estimates from developed countries indicate that asthma accounts for up to 2% of the economic cost of all diseases. A large proportion of asthma-related costs are attributable to poor asthma control. Treatment strategies which improve clinical outcomes in patients with asthma, therefore,...

  • Salmeterol/Fluticasone Propionate: A Review of its Use in the Treatment of Chronic Obstructive Pulmonary Disease. Keating, Gillian M.; McCormack, Paul L. // Drugs;2007, Vol. 67 Issue 16, p2383 

    Salmeterol/fluticasone propionate (Seretide®, Advair®, Viani®) administered using a multidose dry powder inhaler (Diskus®, Accuhaler®) is approved for use in the treatment of chronic obstructive pulmonary disease (COPD) in numerous countries. Salmeterol/fluticasone propionate...

  • Influence of Delivery Devices on Efficacy of Inhaled Fluticasone Propionate: A Comparative Study in Stable Asthma Patients. KOLASANI, BHANU PRAKASH; LANKE, VENU MADHAVI; DIYYA, SUDHEER // Journal of Clinical & Diagnostic Research;Sep2013, Vol. 7 Issue 9, p1908 

    Background: Inhaled corticosteroids are the preferred treatment for long-term control of all grades of persistent asthma. These are administered by various delivery devices with very little information whether these devices can affect the efficacy of inhaled corticosteroids. Fluticasone...

  • fluticasone.  // Taber's Cyclopedic Medical Dictionary;2005, p816 

    A definition of the medical term "fluticasone" is presented. Fluticasone refers to a corticosteroid administered in an aerosol inhaler to treat and prevent asthma. It is also used as a nasal spray to treat seasonal allergic rhinitis, nasal polyps, and other chronic inflammatory conditions; and...

  • Salmeterol and fluticasone propionate given as a combination: Lack of systemic pharmacodynamic and pharmacokinetic interactions. Kirby, S.; Falcoz, C.; Daniel, M. J.; Milleri, S.; Squassante, L.; Ziviani, L.; Ventresca, G. P. // European Journal of Clinical Pharmacology;Jan/Feb2001, Vol. 56 Issue 11, p781 

    Objective: To investigate the potential for systemic pharmacodynamic and pharmacokinetic interactions between inhaled salmeterol and fluticasone propionate when repeat doses of the two drugs are given in combination to healthy subjects. Methods: Twenty-eight healthy subjects received salmeterol...

  • Behavioural changes with fluticasone propionate in children.  // Reactions Weekly;1/27/2007, Issue 1136, p3 

    The article reports on the number of cases of behavioral changes in children linked with the use of inhaled fluticasone propionate or salmeterol/fluticasone propionate received by the Netherlands Pharmacovigilance Centre Lareb. In 11 cases, behavioral changes disappeared when fluticasone...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics